Clinical Trial: Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional

Official Title: Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy

Brief Summary: This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

Detailed Summary: The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in primary central nervous system lymphoma (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.
Sponsor: Navy General Hospital, Beijing

Current Primary Outcome: Overall survival [ Time Frame: 3year Overall survival ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Navy General Hospital, Beijing

Dates:
Date Received: April 23, 2014
Date Started: September 2010
Date Completion: December 2024
Last Updated: September 25, 2016
Last Verified: September 2016